Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maher Albitar

Showing results (151-160 of 214) with videos related to

Pageof 22
Sort By:
British Journal of Haematology|June 29, 2006
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapseFrancis Giles, Srdan Verstovsek, Guillermo Garcia-Manero, et al.
American Journal of Hematology|November 6, 2018
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American expertsNicholas J Short, Elias Jabbour, Maher Albitar, et al.
British Journal of Haematology|January 17, 2007
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemiaFrancis J Giles, Gautam Borthakur, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2009
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndromeWanlong Ma, Hagop Kantarjian, Benjamin Bekele, et al.
Blood|July 20, 2002
Myelodysplastic syndrome is not merely "preleukemia"Maher Albitar, Taghi Manshouri, Yu Shen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignanciesFrancis Giles, Thomas Fischer, Jorge Cortes, et al.
Blood|May 3, 2002
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phaseHagop M Kantarjian, Jorge Cortes, Susan O'Brien, et al.
British Journal of Haematology|May 20, 2003
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expressionFrancis J Giles, B Nebiyou Bekele, Susan O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialDavid P Steensma, Maria R Baer, James L Slack, et al.
Frontiers in Oncology|March 31, 2025
Next-generation sequencing guides diagnosis and treatment in a complex presentation of ALK-positive anaplastic large-cell lymphoma: a case reportTejasvini Vaid, Thomas S Gunning, Rachel Cohen, et al.
Pageof 22

Showing results (151-160 of 214) with videos related to

Sort By:
Pageof 22
British Journal of Haematology|June 29, 2006
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapseFrancis Giles, Srdan Verstovsek, Guillermo Garcia-Manero, et al.
American Journal of Hematology|November 6, 2018
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American expertsNicholas J Short, Elias Jabbour, Maher Albitar, et al.
British Journal of Haematology|January 17, 2007
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemiaFrancis J Giles, Gautam Borthakur, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2009
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndromeWanlong Ma, Hagop Kantarjian, Benjamin Bekele, et al.
Blood|July 20, 2002
Myelodysplastic syndrome is not merely "preleukemia"Maher Albitar, Taghi Manshouri, Yu Shen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignanciesFrancis Giles, Thomas Fischer, Jorge Cortes, et al.
Blood|May 3, 2002
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phaseHagop M Kantarjian, Jorge Cortes, Susan O'Brien, et al.
British Journal of Haematology|May 20, 2003
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expressionFrancis J Giles, B Nebiyou Bekele, Susan O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialDavid P Steensma, Maria R Baer, James L Slack, et al.
Frontiers in Oncology|March 31, 2025
Next-generation sequencing guides diagnosis and treatment in a complex presentation of ALK-positive anaplastic large-cell lymphoma: a case reportTejasvini Vaid, Thomas S Gunning, Rachel Cohen, et al.
Pageof 22